Anticipate generic drug launch
Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Find generic entry opportunities
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Abstract:||Novel compounds of the formula ##STR1## wherein A signifies the group ##STR2## or --(CH.sub.2).sub.5 --, which inhibit pancreas lipase and can be used for the control or prevention of obesity and hyperlipaemia, are disclosed. The inventive compounds can be produced by the cultivation of microorganism Streptomyces toxytricini, identified as NRRL 15443.|
|Inventor(s):||Hadvary; Paul (Biel-Benken, CH), Hochuli; Erich (Arisdorf, CH), Kupfer; Ernst (Basel, CH), Lengsfeld; Hans (Reinach, CH), Weibel; Ernst K. (Pratteln, CH)|
|Assignee:||Hoffmann-La Roche Inc. (Nutley, NJ)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Dosage form; Formulation; Use;|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Switzerland||3415/83||Jun 22, 1983|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.